Crossject SA

Headquarters: Dijon, France

Employees: 85

CEO: Mr. Patrick Alexandre

Euronext: ALCJ -3.08%

Market Cap

€195.9 Million

EUR as of Jan. 1, 2024

US$216.3 Million

Market Cap History

Crossject SA market capitalization over time

Evolution of Crossject SA market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Crossject SA

Detailed Description

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.

Top 1-year algo backtest: +191.38%

$10,000 in June 2023 would now be $29,138 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Crossject SA has the following listings and related stock indices.

Stock: Euronext: ALCJ wb_incandescent

Stock: FSX: 74C wb_incandescent



6 Rue Pauline Kergomard

Dijon, 21000


Phone: 33 3 80 54 98 50